Schneck KB - Search Results

1

Pemetrexed safety and pharmacokinetics in patients with third-space fluid.

Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM. Dickgreber NJ, et al. Among authors: schneck kb. Clin Cancer Res. 2010 May 15;16(10):2872-80. doi: 10.1158/1078-0432.CCR-09-3324. Epub 2010 May 11. Clin Cancer Res. 2010. PMID: 20460481 Free article. Clinical Trial.

2

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.

Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, de Bono J, Tolcher AW, Patnaik A, Monroe P, Wood L, Schneck KB, Clark R, Rowinsky EK. Takimoto CH, et al. Among authors: schneck kb. Clin Cancer Res. 2007 May 1;13(9):2675-83. doi: 10.1158/1078-0432.CCR-06-2393. Clin Cancer Res. 2007. PMID: 17473199 Clinical Trial.

3

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

Abdel-Karim I, Plunkett WK Jr, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. Abdel-Karim I, et al. Among authors: schneck kb. Invest New Drugs. 2011 Apr;29(2):323-31. doi: 10.1007/s10637-009-9369-7. Epub 2010 Jan 21. Invest New Drugs. 2011. PMID: 20091088 Free PMC article. Clinical Trial.

4

Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.

Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM. Posada MM, et al. Among authors: schneck kb. Drug Metab Dispos. 2015 Mar;43(3):325-34. doi: 10.1124/dmd.114.059618. Epub 2014 Dec 12. Drug Metab Dispos. 2015. PMID: 25504564

5

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.

Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. Barrington P, et al. Diabetes Obes Metab. 2011 May;13(5):434-8. doi: 10.1111/j.1463-1326.2011.01365.x. Epub 2011 Jan 19. Diabetes Obes Metab. 2011. PMID: 21251179 Clinical Trial.

6

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, Ellis B, Hardy TA. Barrington P, et al. Diabetes Obes Metab. 2011 May;13(5):426-33. doi: 10.1111/j.1463-1326.2011.01364.x. Epub 2011 Jan 19. Diabetes Obes Metab. 2011. PMID: 21251178 Clinical Trial.

7

Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Zhang X, Schneck K, Bue-Valleskey J, Yeo KP, Heathman M, Sinha V. Zhang X, et al. J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):53-65. doi: 10.1007/s10928-012-9286-9. Epub 2012 Dec 22. J Pharmacokinet Pharmacodyn. 2013. PMID: 23263772 Clinical Trial.

8

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.

Schneck KB, Zhang X, Bauer R, Karlsson MO, Sinha VP. Schneck KB, et al. J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):67-80. doi: 10.1007/s10928-012-9287-8. Epub 2012 Dec 22. J Pharmacokinet Pharmacodyn. 2013. PMID: 23263773 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters